The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens
Source: Fincom Investment Partners for Streetwise Reports  (2/18/20)
Fincom Investment Partners profiles TOMI Environmental Solutions, whose SteraMist disinfectant technology kills the coronavirus. More >

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change
Source: Streetwise Reports  (2/7/20)
Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO. More >

Accuray Shares Rise on Q2 Earnings, Increased Backlog and Raised FY/20 EBITDA Guidance
Source: Streetwise Reports  (1/29/20)
Shares of Accuray traded 15% higher today after the company reported Q2/20 financial results. More >

Co-Diagnostics Utilizes CoPrimer Platform to Design New Coronavirus Detection Test
Source: Streetwise Reports  (1/23/20)
Molecular diagnostics company Co-Diagnostics' shares opened more than 144% higher after the firm reported it has designed a test for virus detection of the new coronavirus, 2019-nCoV, using its CoPrimerâ„¢ platform. More >

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection
Source: Chris Temple for Streetwise Reports  (1/14/20)
Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. More >

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery
Source: Streetwise Reports  (1/14/20)
The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.' More >

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery
Source: Streetwise Reports  (1/14/20)
Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. More >

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Source: Streetwise Reports  (1/13/20)
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. More >

Developer Completes Design Verification of Imaging Device for Bladder Cancer
Source: Streetwise Reports  (1/10/20)
In doing so, it gets one step closer to market approval from U.S. regulators. More >

Microbot Shares Soar on Claims It Has Created the World's First Fully Disposable Endovascular Robotic System
Source: Streetwise Reports  (12/24/19)
Shares of Microbot Medical traded 70% higher after the company reported that in January 2020 it will unveil the world's first fully disposable robotic system for endovascular procedures. The firm claims that its breakthrough technology features compact design, remote operation capabilities and an integrated "One & Done" tool to democratize endovascular procedures. More >

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes
Source: Knox Henderson for Streetwise Reports  (11/13/19)
A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. More >

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue
Source: Streetwise Reports  (11/12/19)
Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results. More >

Dexcom Posts 49% YoY Revenue Growth, Sending Shares to 52-Week High
Source: Streetwise Reports  (11/7/19)
Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance. More >

Fulgent Genetics Hits 52-Week High After Posting 84% Q3 Revenue Increase
Source: Streetwise Reports  (11/5/19)
Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year. More >

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results
Source: Streetwise Reports  (10/29/19)
Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. More >

New Data Could Drive Use of Pancreatic Cancer Early Detection Test
Source: Streetwise Reports  (10/29/19)
The recent results and their implications are provided in an H.C. Wainwright & Co. report. More >

Technical Analyst Expects Health Technologies Firm to Break Higher
Source: Clive Maund for Streetwise Reports  (10/14/19)
Technical analyst Clive Maund outlines the reasons this stock might break higher. More >

Guardant Health Reports Quarterly Revenue Up 178%
Source: Streetwise Reports  (8/7/19)
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million. More >

Biotech's Mosquito Test 'Gains Market Acceptance'
Source: Streetwise Reports  (8/2/19)
This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. More >

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide
Source: Streetwise Reports  (8/2/19)
Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. More >

Technical Analyst: Medical Device Stock Looking Set to Reverse
Source: Clive Maund for Streetwise Reports  (7/12/19)
Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery. More >

Health Technology Company Recuperating Well
Source: Clive Maund for Streetwise Reports  (7/3/19)
Technical analyst Clive Maund charts a medical technology firm and explains why he believes it is an interesting speculative play. More >

Bacteria Test Developer Reiterates Revenue Should Double in 2019
Source: Streetwise Reports  (6/5/19)
The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. More >

Healthcare Firm Partners on Genetic Testing for Cannabis, Medication Responses
Source: Streetwise Reports  (6/3/19)
The offering should facilitate a more individualized treatment plan for patients. More >

Health Tech Firm to Pilot Artificial Intelligence-Powered Patient Monitoring Tool
Source: Streetwise Reports  (4/24/19)
This effort is one way the company can innovatively offer patients care. More >